US52635N1037
US52635N1037
LENZ Therapeutics, Inc.
Loading chart...
Company Profile
LENZ Therapeutics, Inc. operates as a commercial pharmaceutical company that focuses on the development and commercialization of therapies to improve vision in the United States. Its product candidates include VIZZ and LNZ101 for the treatment of presbyopia in adults. LENZ Therapeutics, Inc. was formerly known as Presbyopia Therapies, Inc. and changed its name to LENZ Therapeutics, Inc. in June 2021. The company was founded in 2013 and is headquartered in Solana Beach, California.
Latest News

PR Newswire • 09/09/2026
In HelloNation, Accountant Nils Lenz Explains How Bookkeeping Supports Small Business Success

Motley Fool • 08/19/2026
LENZ Therapeutics (LENZ) Q2 2026 Earnings Call Transcript

Simply Wall St. • 08/15/2026
LENZ Therapeutics (LENZ) Stock Sees Fair Value Moves Lower After Analyst Target Cuts
GuruFocus.com • 08/12/2026
LENZ Therapeutics Inc (LENZ) (Q2 2026) Earnings Call Highlights: VIZZ Launch Momentum ...

Moby • 08/12/2026
LENZ Therapeutics, Inc. Q2 2026 Earnings Call Summary

MarketBeat • 08/11/2026
LENZ Therapeutics Q2 Earnings Call Highlights
Related stocks
Key Metrics & Overview
Detailed metrics & financial data of the company
Company Profile
5
MetricsCountry
Region
Sector
Industry
Website
🛡️ Risk & Structural Analysis
Multi-Factor Risk Model & Market Data
7/7 Very High
5Y Volatility
74.5% p.a.
Max Drawdown (5Y)
-96.5%
Sharpe Ratio (5Y)
-0.68
Beta Factor
1.73
Size Class
Micro Cap
Notes & Warnings
Single Stock Risk: Investing in an individual stock carries full company and insolvency risk (no fund diversification).
Exemplary balance sheet strength: Very solid ratio of equity to debt.
High market risk: Beta of 1.73 indicates above-average volatility compared to the broader market.
🔴 Low analyst coverage – higher uncertainty in growth estimates & projections
Structurally High Volatility: Above-average fluctuations persist across 5 to 10 years (74.5% p.a.).
Historical Stress Test: Maximum peak-to-trough drawdown of -96.5% in the extended horizon.